José Miguel Cisneros

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/796/publications.pdf

Version: 2024-02-01

167 papers

8,596 citations

³⁸⁷⁴² 50 h-index

84 g-index

206 all docs

206 docs citations

206 times ranked 9326 citing authors

#	Article	IF	Citations
1	Seven-versus 14-day course of antibiotics for the treatment of bloodstream infections by Enterobacterales: a randomized, controlled trial. Clinical Microbiology and Infection, 2022, 28, 550-557.	6.0	62
2	Has the COVID-19 pandemic wiped out the seasonality of outpatient antibiotic use and influenza activity? A time-series analysis from 2014 to 2021. Clinical Microbiology and Infection, 2022, 28, 881.e7-881.e12.	6.0	2
3	Factors associated with recruitment success in the phase 2a study of aztreonam–avibactam development programme: a descriptive qualitative analysis among sites in Spain. BMJ Open, 2022, 12, e051187.	1.9	1
4	Seven-versus 14-day course of antibiotics for the treatment of bloodstream infections by enterobacterales: a randomized, controlled trial: authors' response. Clinical Microbiology and Infection, 2022, 28, 739-740.	6.0	3
5	Excretion and viability of SARS-CoV-2 in feces and its association with the clinical outcome of COVID-19. Scientific Reports, 2022, 12, 7397.	3.3	34
6	IgM-enriched immunoglobulin improves colistin efficacy in a pneumonia model by <i>Pseudomonas aeruginosa</i> . Life Science Alliance, 2022, 5, e202101349.	2.8	O
7	A quick prediction tool for unfavourable outcome in COVID-19 inpatients: Development and internal validation. Journal of Infection, 2021, 82, e11-e15.	3.3	15
8	SARS-CoV-2 RNAemia is associated with severe chronic underlying diseases but not with nasopharyngeal viral load. Journal of Infection, 2021, 82, e38-e41.	3.3	16
9	Long-Term Impact of an Educational Antimicrobial Stewardship Program on Management of Patients with Hematological Diseases. Antibiotics, 2021, 10, 136.	3.7	2
10	Do specific antimicrobial stewardship interventions have an impact on carbapenem resistance in Gram-negative bacilli? A multicentre quasi-experimental ecological study: time-trend analysis and characterization of carbapenemases. Journal of Antimicrobial Chemotherapy, 2021, 76, 1928-1936.	3.0	16
11	Impact of an Antimicrobial Stewardship Program on the Incidence of Carbapenem Resistant Gram-Negative Bacilli: An Interrupted Time-Series Analysis. Antibiotics, 2021, 10, 586.	3.7	9
12	Prevalence and Risk Factors for Multidrug-Resistant Organisms Colonization in Long-Term Care Facilities Around the World: A Review. Antibiotics, 2021, 10, 680.	3.7	50
13	SARS-CoV-2 viral load in nasopharyngeal swabs is not an independent predictor of unfavorable outcome. Scientific Reports, 2021, 11, 12931.	3.3	19
14	Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study. Lancet Infectious Diseases, The, 2021, 21, 783-792.	9.1	62
15	Are antimicrobial stewardship interventions effective and safe in long-term care facilities? A systematic review and meta-analysis. Clinical Microbiology and Infection, 2021, 27, 1431-1438.	6.0	16
16	Effect of the coronavirus disease 2019 pandemic on antibiotic use in primary care. Clinical Microbiology and Infection, 2021, 27, 1058-1060.	6.0	28
17	Outcomes of the PIRASOA programme, an antimicrobial stewardship programme implemented in hospitals of the Public Health System of Andalusia, Spain: an ecologic study of time-trend analysis. Clinical Microbiology and Infection, 2020, 26, 358-365.	6.0	30
18	Pharmacokinetics and safety of aztreonam/avibactam for the treatment of complicated intra-abdominal infections in hospitalized adults: results from the REJUVENATE study. Journal of Antimicrobial Chemotherapy, 2020, 75, 618-627.	3.0	60

#	Article	IF	CITATIONS
19	Diversity of amino acid substitutions in PmrCAB associated with colistin resistance in clinical isolates of Acinetobacter baumannii. International Journal of Antimicrobial Agents, 2020, 55, 105862.	2.5	33
20	Long-term impact of an educational antimicrobial stewardship programme in primary care on infections caused by extended-spectrum \hat{l}^2 -lactamase-producing Escherichia coli in the community: an interrupted time-series analysis. Lancet Infectious Diseases, The, 2020, 20, 199-207.	9.1	42
21	Impact of the COVID-19 Pandemic on Antimicrobial Consumption and Hospital-Acquired Candidemia and Multidrug-Resistant Bloodstream Infections. Antibiotics, 2020, 9, 816.	3.7	42
22	Defining persistent Staphylococcus aureus bacteraemia: secondary analysis of a prospective cohort study. Lancet Infectious Diseases, The, 2020, 20, 1409-1417.	9.1	84
23	A Randomized, Double-Blind, Placebo-Controlled Trial (TAURCAT Study) of Citrate Lock Solution for Prevention of Endoluminal Central Venous Catheter Infection in Neutropenic Hematological Patients. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	10
24	Efficacy and safety of a comprehensive educational antimicrobial stewardship program focused on antifungal use. Journal of Infection, 2020, 80, 342-349.	3.3	13
25	Clinical impact of an educational antimicrobial stewardship program associated with infectious diseases consultation targeting patients with cancer: Results of a 9-year quasi-experimental study with an interrupted time-series analysis. Journal of Infection, 2019, 79, 206-211.	3.3	3
26	High incidence of MDR and XDR Pseudomonas aeruginosa isolates obtained from patients with ventilator-associated pneumonia in Greece, Italy and Spain as part of the MagicBullet clinical trial. Journal of Antimicrobial Chemotherapy, 2019, 74, 1244-1252.	3.0	64
27	Combined Use of the Ab105-2φΔCI Lytic Mutant Phage and Different Antibiotics in Clinical Isolates of Multi-Resistant Acinetobacter baumannii. Microorganisms, 2019, 7, 556.	3.6	33
28	Colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia (Magic) Tj $ETQq0\ 0\ 0$ Care, 2019, 23, 383.	rgBT /Over 5.8	erlock 10 Tf 50 53
29	A multimodal intervention program to control a long-term Acinetobacter baumannii endemic in a tertiary care hospital. Antimicrobial Resistance and Infection Control, 2019, 8, 199.	4.1	24
30	Next Step, Outpatient Antimicrobial Therapy Programs as a Tool of Stewardship Programs. Clinical Infectious Diseases, 2019, 68, 2155-2155.	5.8	5
31	Usefulness of guideline recommendations for prognosis in patients with candidemia. Medical Mycology, 2019, 57, 659-667.	0.7	24
32	Investigation of Novel <i>pmrB</i> and <i>eptA</i> Mutations in Isogenic Acinetobacter baumannii Isolates Associated with Colistin Resistance and Increased Virulence <i>In Vivo</i> Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	60
33	Antimicrobial defined daily dose adjusted by weight: a proposal for antibiotic consumption measurement in children. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2019, 37, 301-306.	0.5	19
34	Impact of De-escalation on Prognosis of Patients With Bacteremia due to Enterobacteriaceae: A Post Hoc Analysis From a Multicenter Prospective Cohort. Clinical Infectious Diseases, 2019, 69, 956-962.	5.8	18
35	La crisis de los antibióticos: profesionales sanitarios, ciudadanos y polÃŧicos, todos somos responsables. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2018, 36, 259-261.	0.5	4
36	Novel Indicators for Enhancing the Clinical Outcome Metrics of Antimicrobial Stewardship Programs. Infection Control and Hospital Epidemiology, 2018, 39, 758-759.	1.8	2

#	Article	IF	Citations
37	Antibiotic treatment of infections caused by carbapenem-resistant Gram-negative bacilli: an international ESCMID cross-sectional survey among infectious diseases specialists practicing in large hospitals. Clinical Microbiology and Infection, 2018, 24, 1070-1076.	6.0	58
38	Evaluation of the impact of a nationwide massive online open course on the appropriate use of antimicrobials. Journal of Antimicrobial Chemotherapy, 2018, 73, 2231-2235.	3.0	10
39	Management of multidrug resistant Gram-negative bacilli infections in solid organ transplant recipients: SET/GESITRA-SEIMC/REIPI recommendations. Transplantation Reviews, 2018, 32, 36-57.	2.9	104
40	The combined use of tigecycline with high-dose colistin might not be associated with higher survival in critically ill patients with bacteraemia due to carbapenem-resistant Acinetobacter baumannii. Clinical Microbiology and Infection, 2018, 24, 630-634.	6.0	41
41	Antimicrobial stewardship in Spain: Programs for Optimizing the use of Antibiotics (PROA) in Spanish hospitals. Germs, 2018, 8, 109-112.	1.3	7
42	Relationship Between the Quorum Network (Sensing/Quenching) and Clinical Features of Pneumonia and Bacteraemia Caused by A. baumannii. Frontiers in Microbiology, 2018, 9, 3105.	3 . 5	14
43	Predictors of outcome in patients with severe sepsis or septic shock due to extended-spectrum Î ² -lactamase-producing Enterobacteriaceae. International Journal of Antimicrobial Agents, 2018, 52, 577-585.	2.5	36
44	Direct-acting antivirals are effective and safe in HCV/HIV-coinfected liver transplant recipients who experience recurrence of hepatitis C: A prospective nationwide cohort study. American Journal of Transplantation, 2018, 18, 2513-2522.	4.7	32
45	Application of BioFire FilmArray Blood Culture Identification panel for rapid identification of the causative agents of ventilator-associated pneumonia. Clinical Microbiology and Infection, 2018, 24, 1213.e1-1213.e4.	6.0	29
46	Administration of taurolidine-citrate lock solution for prevention of central venous catheter infection in adult neutropenic haematological patients: a randomised, double-blinded, placebo-controlled trial (TAURCAT). Trials, 2018, 19, 264.	1.6	10
47	Rapid Detection of Antibiotic Resistance in Gram-Negative Bacteria Through Assessment of Changes in Cellular Morphology. Microbial Drug Resistance, 2017, 23, 157-162.	2.0	15
48	Time to positivity of blood cultures in patients with bloodstream infections: A useful prognostic tool. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2017, 35, 638-644.	0.5	12
49	MIC of amoxicillin/clavulanate according to CLSI and EUCAST: discrepancies and clinical impact in patients with bloodstream infections due to Enterobacteriaceae. Journal of Antimicrobial Chemotherapy, 2017, 72, dkw562.	3.0	17
50	Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infectious Diseases, The, 2017, 17, 726-734.	9.1	367
51	Overproduction of outer membrane protein A (OmpA) by <i>Acinetobacter baumannii</i> is a risk factor for nosocomial pneumonia, bacteremia and mortality increase Journal of Infectious Diseases, 2017, 215, jix010.	4.0	42
52	Optimisation of empirical antimicrobial therapy in patients with haematological malignancies and febrile neutropenia (How Long study): an open-label, randomised, controlled phase 4 trial. Lancet Haematology,the, 2017, 4, e573-e583.	4.6	161
53	Response to Bile Salts in Clinical Strains of Acinetobacter baumannii Lacking the AdeABC Efflux Pump: Virulence Associated with Quorum Sensing. Frontiers in Cellular and Infection Microbiology, 2017, 7, 143.	3.9	40
54	High incidence of pandrug-resistant Acinetobacter baumannii isolates collected from patients with ventilator-associated pneumonia in Greece, Italy and Spain as part of the MagicBullet clinical trial. Journal of Antimicrobial Chemotherapy, 2017, 72, 3277-3282.	3.0	175

#	Article	IF	CITATIONS
55	Long-Term Impact of an Educational Antimicrobial Stewardship Program on Hospital-Acquired Candidemia and Multidrug-Resistant Bloodstream Infections: A Quasi-Experimental Study of Interrupted Time-Series Analysis. Clinical Infectious Diseases, 2017, 65, 1992-1999.	5.8	61
56	Quorum sensing network in clinical strains of A. baumannii: AidA is a new quorum quenching enzyme. PLoS ONE, 2017, 12, e0174454.	2.5	54
57	Liver Retransplantation in Patients With HIV-1 Infection: An International Multicenter Cohort Study. American Journal of Transplantation, 2016, 16, 679-687.	4.7	11
58	A Multinational, Preregistered Cohort Study of \hat{l}^2 -Lactam \hat{l}^2 -Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum- \hat{l}^2 -Lactamase-Producing Enterobacteriaceae. Antimicrobial Agents and Chemotherapy, 2016, 60, 4159-4169.	3.2	137
59	Clinical validation of a real-time polymerase chain reaction assay for rapid detection of Acinetobacter baumannii colonization. Journal of Hospital Infection, 2016, 94, 68-71.	2.9	2
60	A Predictive Model of Mortality in Patients With Bloodstream Infections due to Carbapenemase-Producing Enterobacteriaceae. Mayo Clinic Proceedings, 2016, 91, 1362-1371.	3.0	89
61	Genomic Evolution of Two Acinetobacter baumannii Clinical Strains from ST-2 Clones Isolated in 2000 and 2010 (ST-2_clon_2000 and ST-2_clon_2010). Genome Announcements, 2016, 4, .	0.8	6
62	Human immunodeficiency virus infection does not worsen prognosis of liver transplantation for hepatocellular carcinoma. Hepatology, 2016, 63, 488-498.	7. 3	27
63	Acinetobacter baumannii in critically ill patients: Molecular epidemiology, clinical features and predictors of mortality. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2016, 34, 551-558.	0.5	23
64	Optimizing the Clinical Use of Vancomycin. Antimicrobial Agents and Chemotherapy, 2016, 60, 2601-2609.	3.2	182
65	Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study. Journal of Antimicrobial Chemotherapy, 2016, 71, 1672-1680.	3.0	41
66	Impact of the MIC of piperacillin/tazobactam on the outcome for patients with bacteraemia due to Enterobacteriaceae: the Bacteraemia-MIC project. Journal of Antimicrobial Chemotherapy, 2016, 71, 521-530.	3.0	21
67	Colistin Dosage without Loading Dose Is Efficacious when Treating Carbapenem-Resistant Acinetobacter baumannii Ventilator-Associated Pneumonia Caused by Strains with High Susceptibility to Colistin. PLoS ONE, 2016, 11, e0168468.	2.5	12
68	Early oral switch therapy in low-risk Staphylococcus aureus bloodstream infection (SABATO): study protocol for a randomized controlled trial. Trials, 2015, 16, 450.	1.6	42
69	Diagnosis and antimicrobial treatment of invasive infections due to multidrug-resistant Enterobacteriaceae. Guidelines of the Spanish Society of Infectious Diseases and Clinical Microbiology. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2015, 33, 337.e1-337.e21.	0.5	29
70	Executive summary of the diagnosis and antimicrobial treatment of invasive infections due to multidrug-resistant Enterobacteriaceae. Guidelines of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2015, 33, 338-341.	0.5	23
71	Executive summary. Management of urinary tract infection in solid organ transplant recipients: Consensus statement of the Group for the Study of Infection in Transplant Recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) and the Spanish Network for Research in Infectious Diseases (REIPI). Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2015, 33,	0.5	14
72	<i>Editorial Commentary</i> : A Chance to Change the Paradigm of Outcome Assessment of Antimicrobial Stewardship Programs: Figure 1 Clinical Infectious Diseases, 2015, 61, 807-808.	5.8	21

#	Article	IF	CITATIONS
73	Safety and efficacy of colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia as part of a macro-project funded by the Seventh Framework Program of the European Commission studying off-patent antibiotics: study protocol for a randomized controlled trial. Trials, 2015, 16, 102.	1.6	17
74	Task force on management and prevention of Acinetobacter baumannii infections in the ICU. Intensive Care Medicine, 2015, 41, 2057-2075.	8.2	133
7 5	Reduced susceptibility to biocides in Acinetobacter baumannii: association with resistance to antimicrobials, epidemiological behaviour, biological cost and effect on the expression of genes encoding porins and efflux pumps. Journal of Antimicrobial Chemotherapy, 2015, 70, 3222-3229.	3.0	65
76	Management of urinary tract infection in solid organ transplant recipients: Consensus statement of the Group for the Study of Infection in Transplant Recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) and the Spanish Network for Research in Infectious Diseases (REIPI). Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2015, 33, 679.e1-679.e21.	0.5	29
77	Treatment of infections caused by carbapenemase-producing Enterobacteriaceae. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2014, 32, 49-55.	0.5	9
78	Chryseobacterium indologenes central nervous system infection in infancy: an emergent pathogen?. Infection, 2014, 42, 179-183.	4.7	22
79	Prevention strategies for cytomegalovirus disease and longâ€ŧerm outcomes in the highâ€₅isk transplant patient (D+/Râ°): experience from the <scp>RESITRA</scp> â€∢scp>REIPI cohort. Transplant Infectious Disease, 2014, 16, 387-396.	1.7	25
80	Characterization of plasmids carrying the blaOXA-24/40 carbapenemase gene and the genes encoding the AbkA/AbkB proteins of a toxin/antitoxin system*. Journal of Antimicrobial Chemotherapy, 2014, 69, 2629-2633.	3.0	43
81	Antifungal Combination Therapy for Invasive Aspergillosis. Clinical Infectious Diseases, 2014, 59, 1437-1445.	5.8	32
82	Timing of CMV-specific effector memory T cells predicts viral replication and survival after allogeneic hematopoietic stem cell transplantation. Transplant International, 2014, 27, 1253-1262.	1.6	12
83	Escherichia coli belonging to the worldwide emerging epidemic clonal group O25b/ST131: risk factors and clinical implications. Journal of Antimicrobial Chemotherapy, 2014, 69, 809-814.	3.0	52
84	Monotherapy versus combination therapy for sepsis due to multidrug-resistant Acinetobacter baumannii: analysis of a multicentre prospective cohort. Journal of Antimicrobial Chemotherapy, 2014, 69, 3119-3126.	3.0	81
85	Clinical impact of neutropenia related with the preemptive therapy of CMV infection in solid organ transplant recipients. Journal of Infection, 2014, 69, 500-506.	3.3	22
86	Does the current treatment of invasive fungal infection need to be reviewed?. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2014, 32, 523-528.	0.5	4
87	Global impact of an educational antimicrobial stewardship programme on prescribing practice in a tertiary hospital centre. Clinical Microbiology and Infection, 2014, 20, 82-88.	6.0	80
88	Epidemiologic and Clinical Impact of Acinetobacter baumannii Colonization and Infection. Medicine (United States), 2014, 93, 202-210.	1.0	53
89	Progress on the development of rapid methods for antimicrobial susceptibility testing. Journal of Antimicrobial Chemotherapy, 2013, 68, 2710-2717.	3.0	187
90	Contribution of Efflux Pumps, Porins, and \hat{I}^2 -Lactamases to Multidrug Resistance in Clinical Isolates of Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy, 2013, 57, 5247-5257.	3.2	170

#	Article	IF	CITATIONS
91	Education on antibiotic use. Education systems and activities that work. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2013, 31, 31-37.	0.5	7
92	Escherichia coli O25b:H4/ST131 are prevalent in Spain and are often not associated with ESBL or quinolone resistance. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2013, 31, 385-388.	0.5	22
93	Poor antimicrobial training of clinicians in Spain. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2013, 31, 197-198.	0.5	2
94	Determination, validation and standardization of a CMV DNA cut-off value in plasma for preemptive treatment of CMV infection in solid organ transplant recipients at lower risk for CMV infection. Journal of Clinical Virology, 2013, 56, 13-18.	3.1	58
95	Rapid Determination of Colistin Resistance in Clinical Strains of Acinetobacter baumannii by Use of the Micromax Assay. Journal of Clinical Microbiology, 2013, 51, 3675-3682.	3.9	8
96	Cost-Effectiveness Analysis Comparing Two Approaches for Empirical Antifungal Therapy in Hematological Patients with Persistent Febrile Neutropenia. Antimicrobial Agents and Chemotherapy, 2013, 57, 4664-4672.	3.2	13
97	Selection Bias in Andes et al. Clinical Infectious Diseases, 2012, 55, 893-894.	5.8	8
98	Universal antifungal therapy is not needed in persistent febrile neutropenia: a tailored diagnostic and therapeutic approach. Haematologica, 2012, 97, 464-471.	3.5	35
99	Antimicrobial and immunosuppressive drug interactions in solid organ transplant recipients. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2012, 30, 86-92.	0.5	9
100	Time to positivity of blood culture association with clinical presentation, prognosis and ESBL-production in Escherichia coli bacteremia. European Journal of Clinical Microbiology and Infectious Diseases, 2012, 31, 2191-2195.	2.9	20
101	Outcome of <i>Clostridium difficile-</i> associated disease in solid organ transplant recipients: a prospective and multicentre cohort study. Transplant International, 2012, 25, 1275-1281.	1.6	38
102	Preemptive Therapy in the Prevention of Cytomegalovirus Disease in High- and Low-Risk Heart Transplant Recipients. Transplantation Proceedings, 2012, 44, 2113-2114.	0.6	3
103	Tunneled Hemodialysis Catheter-Related Bloodstream Infections: A Prospective Multicenter Cohort Study from Spain. Journal of Vascular Access, 2012, 13, 239-245.	0.9	11
104	Virulence Profiles of Bacteremic Extended-Spectrum \hat{l}^2 -Lactamase-Producing Escherichia coli: Association with Epidemiological and Clinical Features. PLoS ONE, 2012, 7, e44238.	2.5	35
105	GESITRA-SEIMC/REIPI recommendations for the management of cytomegalovirus infection in solid-organ transplant patients. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2011, 29, 735-758.	0.5	78
106	Therapeutic Effect of the Acquisition of Cytomegalovirus-Specific Immune Response During Preemptive Treatment. Transplantation, 2011, 91, 927-933.	1.0	45
107	Prospective study of infectious complications in allogeneic hematopoietic stem cell transplant recipients. Clinical Transplantation, 2011, 25, 468-474.	1.6	36
108	Pneumonia in allogeneic stem cell transplantation recipients: a multicenter prospective study. Clinical Transplantation, 2011, 25, E629-E638.	1.6	68

#	Article	IF	CITATIONS
109	Empirical antifungal therapy in selected patients with persistent febrile neutropenia. Bone Marrow Transplantation, 2010, 45, 159-164.	2.4	22
110	Risk Factors and Prognosis of Nosocomial Bloodstream Infections Caused by Extended-Spectrum-I ² -Lactamase-Producing <i>Escherichia coli</i> . Journal of Clinical Microbiology, 2010, 48, 1726-1731.	3.9	144
111	Clinical Features of Infections and Colonization by <i>Acinetobacter</i> Genospecies 3. Journal of Clinical Microbiology, 2010, 48, 4623-4626.	3.9	12
112	Risk Factors for Fluconazole-Resistant Candidemia. Antimicrobial Agents and Chemotherapy, 2010, 54, 3149-3154.	3.2	97
113	Clinical Utility of Real-Time Polymerase Chain Reaction to Quantify Cytomegalovirus Replication in Allogeneic Stem Cell Transplant Recipients With Different Prevention Strategies. Transplantation Proceedings, 2010, 42, 3228-3229.	0.6	2
114	Differences in Cytomegalovirus Replication Quantified Using Quantitative Polymerase Chain Reaction and Antigenemia After Allogeneic Stem Cell Transplantation. Transplantation Proceedings, 2010, 42, 3230-3231.	0.6	4
115	Tuberculosis after Solidâ€Organ Transplant: Incidence, Risk Factors, and Clinical Characteristics in the RESITRA (Spanish Network of Infection in Transplantation) Cohort. Clinical Infectious Diseases, 2009, 48, 1657-1665.	5.8	251
116	Escherichia coli producing SHV-type extended-spectrum Â-lactamase is a significant cause of community-acquired infection. Journal of Antimicrobial Chemotherapy, 2009, 63, 781-784.	3.0	24
117	Prospective study of infectious complications in a cohort of pediatric renal transplant recipients. Pediatric Transplantation, 2009, 13, 457-463.	1.0	28
118	Genetic Variability among $\langle i \rangle$ ampC $\langle i \rangle$ Genes from $\langle i \rangle$ Acinetobacter $\langle i \rangle$ Genomic Species 3. Antimicrobial Agents and Chemotherapy, 2009, 53, 1177-1184.	3.2	21
119	In vitro susceptibilities of bloodstream isolates of Candida spp.: results from a multicenter active surveillance program in Andalusia. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2009, 27, 518-522.	0.5	7
120	Nosocomial Outbreak of Infection With Pan–Drug-Resistant <i>Acinetobacter baumannii</i> i>in a Tertiary Care University Hospital. Infection Control and Hospital Epidemiology, 2009, 30, 257-263.	1.8	202
121	Prophylaxis With Caspofungin for Invasive Fungal Infections in High-Risk Liver Transplant Recipients. Transplantation, 2009, 87, 424-435.	1.0	99
122	Prevention of cytomegalovirus disease using preemptive treatment after solid organ transplant in patients at high risk for cytomegalovirus infection. Antiviral Therapy, 2009, 14, 641-647.	1.0	16
123	Biofilm formation in Acinetobacter baumannii: associated features and clinical implications. Clinical Microbiology and Infection, 2008, 14, 276-278.	6.0	196
124	Incisional surgical infection in heart transplantation. Transplant Infectious Disease, 2008, 10, 298-302.	1.7	34
125	Preemptive Therapy for Cytomegalovirus Disease in Allogeneic Stem Cell Transplant Recipients. Transplantation Proceedings, 2008, 40, 3102-3103.	0.6	4
126	Incisional Surgical Site Infection in Kidney Transplantation. Urology, 2008, 72, 119-123.	1.0	48

#	Article	IF	Citations
127	Valganciclovir as Treatment for Cytomegalovirus Disease in Solid Organ Transplant Recipients. Clinical Infectious Diseases, 2008, 46, 20-27.	5.8	71
128	Sirolimus-Associated Pneumonitis in Heart Transplant Recipients. Annals of Pharmacotherapy, 2008, 42, 1143-1145.	1.9	11
129	Community Infections Caused by Extended-Spectrum β-Lactamase–Producing Escherichia coli. Archives of Internal Medicine, 2008, 168, 1897.	3.8	333
130	Surgical Site Infection in Liver Transplant Recipients: Impact of the Type of Perioperative Prophylaxis. Transplantation, 2008, 85, 1849-1854.	1.0	63
131	False extended-spectrum Â-lactamase detection in Acinetobacter spp. due to intrinsic susceptibility to clavulanic acid. Journal of Antimicrobial Chemotherapy, 2007, 61, 301-308.	3.0	10
132	Changes in the incidence of tuberculosis in a cohort of HIV-seroconverters before and after the introduction of HAART. Aids, 2007, 21, 2521-2527.	2.2	35
133	Update on invasive fungal infections: the last two years. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2007, 25, 19-27.	0.5	O
134	Pneumonia After Lung Transplantation in the Resitra Cohort: A Multicenter Prospective Study. American Journal of Transplantation, 2007, 7, 1989-1996.	4.7	178
135	Bloodstream Infections Among Transplant Recipients: Results of a Nationwide Surveillance in Spain1. American Journal of Transplantation, 2007, 7, 2579-2586.	4.7	191
136	Epidemiology of Urinary Infections in Renal Transplant Recipients. Transplantation Proceedings, 2006, 38, 2414-2415.	0.6	114
137	Infections in Cardiac Transplant Recipients: Clinical and Microbiological Characteristics and Consequences. Transplantation Proceedings, 2006, 38, 2555-2557.	0.6	9
138	Trends in AIDS and Mortality in HIV-Infected Subjects With Hemophilia From 1985 to 2003. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 41, 624-631.	2.1	30
139	Therapeutic armamentarium against systemic fungal infections. Clinical Microbiology and Infection, 2006, 12, 53-64.	6.0	2
140	Quantitative pp65 antigenemia in the diagnosis of cytomegalovirus disease: prospective assessment in a cohort of solid organ transplant recipients. Journal of Infection, 2005, 51, 188-194.	3.3	19
141	Hospital outbreak caused by a carbapenem-resistant strain of Acinetobacter baumannii: patient prognosis and risk-factors for colonisation and infection. Clinical Microbiology and Infection, 2005, 11, 540-546.	6.0	127
142	Risk-factors for the acquisition of imipenem-resistant Acinetobacter baumannii in Spain: a nationwide study. Clinical Microbiology and Infection, 2005, 11, 874-879.	6.0	102
143	Discontinuation of Antiretroviral Therapy in Patients with Chronic HIV Infection: Clinical, Virologic, and Immunologic Consequences. AIDS Patient Care and STDs, 2005, 19, 550-562.	2.5	29
144	Comparative Study of Muromonab-CD3 (OKT3) Versus Daclizumab (Zenapax) in Cardiac Transplantation at Our Center. Transplantation Proceedings, 2005, 37, 1548-1549.	0.6	8

#	Article	IF	Citations
145	Antimicrobial Susceptibility and Mechanisms of Resistance to Quinolones and \hat{l}^2 -Lactams in Acinetobacter Genospecies 3. Antimicrobial Agents and Chemotherapy, 2004, 48, 1430-1432.	3.2	17
146	Type 1 Integrons in Epidemiologically Unrelated Acinetobacter baumannii Isolates Collected at Spanish Hospitals. Antimicrobial Agents and Chemotherapy, 2004, 48, 364-365.	3. 2	30
147	Double-Chambered Right Ventricle Associated with Mural and Pulmonic Valve Endocarditis: Description of a Clinical Case and Review of the Literature. Echocardiography, 2004, 21, 171-173.	0.9	23
148	Safety of the concomitant use of caspofungin and cyclosporin A in patients with invasive fungal infections. Bone Marrow Transplantation, 2004, 34, 13-20.	2.4	79
149	Clinical Features and Epidemiology of Acinetobacter baumannii Colonization and Infection in Spanish Hospitals. Infection Control and Hospital Epidemiology, 2004, 25, 819-824.	1.8	130
150	Diversidad clonal y sensibilidad a los antimicrobianos de Acinetobacter baumannii aislados en hospitales españoles. Estudio multicéntrico nacional: proyecto GEIH-Ab 2000. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2004, 22, 267-271.	0.5	15
151	Trasplante hepático en pacientes con infección por el VIH: una realidad en el año 2004. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2004, 22, 529-538.	0.5	7
152	Comparison of monitoring trough and peak cyclosporine levels in heart transplantation. Transplantation Proceedings, 2003, 35, 727-728.	0.6	0
153	Preemptive therapy for the prevention of cytomegalovirus disease following heart transplantation directed by PP65 antigenemia. Transplantation Proceedings, 2003, 35, 732-734.	0.6	9
154	Characteristics and repercussion of varicella-zoster virus infection in cardiac transplant. Transplantation Proceedings, 2003, 35, 2004-2005.	0.6	9
155	Prevalence of sleep breathing disorders in outpatients on a heart transplant waiting list. Transplantation Proceedings, 2003, 35, 1944-1945.	0.6	8
156	Effectiveness of highly active antiretroviral therapy in Spanish cohorts of HIV seroconverters. Aids, 2003, 17, 353-359.	2.2	89
157	Acinetobacter baumannii: un patógeno nosocomial de difÃcil control. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2003, 21, 221-223.	0.5	4
158	Comparison of a Repetitive Extragenic Palindromic Sequence-Based PCR Method and Clinical and Microbiological Methods for Determining Strain Sources in Cases of Nosocomial <i>Acinetobacter baumannii</i> Bacteremia. Journal of Clinical Microbiology, 2002, 40, 4571-4575.	3.9	46
159	Medical management of pneumonia caused by Rhodococcus equi in a renal transplant recipient. American Journal of Kidney Diseases, 2002, 39, e7.1-e7.4.	1.9	14
160	Infections in Renal Transplant Recipients Receiving Mycophenolate Versus Azathioprine-Based Immunosuppression. European Journal of Clinical Microbiology and Infectious Diseases, 2002, 21, 173-180.	2.9	48
161	Nosocomial bacteremia due to Acinetobacter baumannii: epidemiology, clinical features and treatment. Clinical Microbiology and Infection, 2002, 8, 687-693.	6.0	246
162	Sobre la patogenicidad de Enterococcus spp. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2001, 19, 184.	0.5	0

#	Article	IF	CITATIONS
163	Attributable Mortality Rate and Duration of Hospital Stay Associated with Enterococcal Bacteremia. Clinical Infectious Diseases, 2001, 32, 587-594.	5.8	86
164	Suppurative mediastinis after heart transplantation: early diagnosis with ct-guided needle aspiration. Journal of Heart and Lung Transplantation, 2000, 19, 512-514.	0.6	9
165	Pneumonia After Heart Transplantation: A Multiinstitutional Study. Clinical Infectious Diseases, 1998, 27, 324-331.	5 . 8	106
166	Comparative Study of Bacteremias Caused by <i>Enterococcus</i> spp. with and without High-Level Resistance to Gentamicin. Journal of Clinical Microbiology, 1998, 36, 520-525.	3.9	55
167	Impact of a Carbapenem Stewardship Programme on the Incidence of Carbapenem-Resistant Gram-Negative Bacilli: An Interrupted Time-Series Analysis. SSRN Electronic Journal, 0, , .	0.4	0